- Home
- NTRB vs YI Comparison
NTRB vs YI Comparison
Compare NTRB & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- YI
- Stock Information
- Founded
- NTRB 2016
- YI 2010
- Country
- NTRB United States
- YI China
- Employees
- NTRB N/A
- YI N/A
- Industry
- NTRB Industrial Specialties
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- NTRB Health Care
- YI Consumer Staples
- Exchange
- NTRB Nasdaq
- YI Nasdaq
- Market Cap
- NTRB 77.9M
- YI 71.1M
- IPO Year
- NTRB N/A
- YI N/A
- Fundamental
- Price
- NTRB $4.37
- YI $0.77
- Analyst Decision
- NTRB
- YI
- Analyst Count
- NTRB 0
- YI 0
- Target Price
- NTRB N/A
- YI N/A
- AVG Volume (30 Days)
- NTRB 27.6K
- YI 182.3K
- Earning Date
- NTRB 12-04-2024
- YI 11-27-2024
- Dividend Yield
- NTRB N/A
- YI N/A
- EPS Growth
- NTRB N/A
- YI N/A
- EPS
- NTRB N/A
- YI N/A
- Revenue
- NTRB $2,021,771.00
- YI $2,090,255,896.00
- Revenue This Year
- NTRB N/A
- YI $61.85
- Revenue Next Year
- NTRB N/A
- YI N/A
- P/E Ratio
- NTRB N/A
- YI N/A
- Revenue Growth
- NTRB N/A
- YI N/A
- 52 Week Low
- NTRB $2.22
- YI $0.55
- 52 Week High
- NTRB $9.60
- YI $1.85
- Technical
- Relative Strength Index (RSI)
- NTRB 47.75
- YI 52.81
- Support Level
- NTRB $3.87
- YI $0.75
- Resistance Level
- NTRB $4.86
- YI $0.85
- Average True Range (ATR)
- NTRB 0.48
- YI 0.06
- MACD
- NTRB 0.08
- YI 0.00
- Stochastic Oscillator
- NTRB 65.05
- YI 35.29
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.